Relationship between Hba1c and blood glucose level in hemodialysis patients with diabetes mellitus

Yıl 2013, Cilt: 40 Sayı: 4, 616 - 620, 01.12.2013

Sedat Motor Recep Dokuyucu Fatih Sefil M. Murat Rifaioğlu Erhan Yengil Kemal Türker Ulutaş Ahmet Taner Sümbül Hatice Rızaoglu İhsan Üstün Cumali Gökçe

https://doi.org/10.5798/diclemedj.0921.2013.04.0343

Cited By: 2

Öz

Objective: Within in the scope of this study, a research was aimed at the relationship between HbA1c markers and blood glucose levels with DM, chronic renal failure and receiving dialysis treatment. Methods: In this study, monthly glucose levels and quarterly HbA1c markers of 131 patients (53 female, 78 male) receiving dialysis treatment in a private dialysis center between January 1, 2009-July 31, 2010 were evaluated retrospectively. Results: The average age of 131 cases was 63.3±11.2 years (range, 30-91). Gender distribution of the cases: 53 female (40.5%), 78 male (59.5%). While the age average of the females was 62.2±11.2 and the males' was 64.1±11.2. The average glucose level of the females and males have a correlation to average HbA1c (Female: p

Anahtar Kelimeler

Hemodialysis, diabetes mellitus, HbA1c

Diabetes mellituslu hemodiyaliz hastalarında HbA1c ile kan glukozu düzeyleri arasındaki ilişki

Öz

Amaç: Bu çalışmada Diabetes mellitus (DM)\'lu, kronik böbrek yetmezliği olan ve diyalize giren hastalarda HbA1c düzeyleri ile kan glukozu düzeyleri arasındaki ilişkinin incelenmesi amaçlanmıştır. Yöntemler: 1 Ocak 2009-31 Temmuz 2010 tarihleri arasında, özel bir diyaliz merkezinde diyalize giren 131 (53 kadın, 78 erkek) hastanın aylık kan glukozu ve 3 aylık HbA1c sonuçları geriye dönük olarak incelendi. Bulgular: 131 olgunun yaş ortalaması 63,3±11,2 yıl (30-91 yaş arası) idi. Bu olguların 53\'ü kadın (%40,5), 78\'i erkek (%59.5) idi. Kadınların yaş ortalaması 62,2±11,2 iken erkeklerin yaş ortalaması 64,1±11,2 idi. Kadınların ve erkeklerin ortalama glukoz değeri ile ortalama HbA1c değeri arasında korelasyon vardı (Kadın: p

Anahtar Kelimeler

Hemodiyaliz, diyabet, glikolize hemoglobin

Kaynakça

• Tierney LM, McPhee SJ, Papadakis MA. Current medical Diagnosis & Treatment International edition New York Lange Medical Books/McGraw-Hill 2002;1203-1215.
• Hasselbaink DM, Glatz JF, Luiken JJ, et al. Ketone bod- ies disturb fatty acid handling in isolated cardiomyo- cytes derived from control and diabetic rats. Biochem J 2003;371:753-760.
• Abou-Seif MA, Youssef AA. Evaluation of some biochemical changes in diabetic patients. Clin Chim Acta 2004;346:161- 170.
• Expert Committee on the D, Classification of Diabetes M. Report of the expert committee on the diagnosis and clas- sification of diabetes mellitus. Diabetes Care 2003;26:5-20.
• Tietz Textbook of Clinical Chemistry. Burtis CA Ashwood ER eds. Third Edition 2003;790-796.
• The effect of intensive treatment of diabetes on the devel- opment and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-986.
• Intensive blood-glucose control with sulphonylureas or in- sulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group Lan- cet 1998;352:837-853.
• Foley RN, Collins AJ. The growing economic burden of dia- betic kidney disease. Curr Diab Rep 2009;9:460-465.
• Israel E, Geara A, Maarouf O, et al. Correlation between gly- cated hemoglobin and mean plasma glucose in hemodialy- sis patients. Int Urol Nephrol 2011;43:1149-1153.
• World Health Organization Study Group. Diabetes mellitus. Geneva: World Health Org; Tech Rep Ser 727 1985;99
• Report of the Expert Committee on the Diagnosis and Classi- fication of Diabetes Mellitus. Diabetes Care 1997;20:1183- 1197.
• Summary of revisions for the 2010 Clinical Practice Rec- ommendations. Diabetes Care 2010;33:S3
• Mogensen CE, Christensen CK, Vittinghus E. The stages in diabetic renal disease With emphasis on the stage of incipi- ent diabetic nephropathy. Diabetes 1983;32:64-78.
• Krolewski AS, Laffel LM, Krolewski M, et al. Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. N Engl J Med 1995;332:1251-1255.
• Warram JH, Scott LJ, Hanna LS, et al. Progression of mi- croalbuminuria to proteinuria in type 1 diabetes: nonlinear relationship with hyperglycemia. Diabetes 2000;49:94-100.
• Reutens AT, Prentice L, Atkins R. The epidemiology of dia- betic kidney disease. In: Ekoé J, Rewers M, Williams R, Zimmet P (eds) The epidemiology of diabetes mellitus, 2nd ed. John Wiley & Sons, Chichester 2008;499–518.
• National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: International compari- sons, in 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Maryland; Bethesda 2007;239–254.
• Parving HH, Hovind P, Rossing K, Andersen S. Evolving strategies for renoprotection: diabetic nephropathy. Curr Opin Nephrol Hypertens 2001;10:515-522.
• Hsueh WA, Moore L, Bryer-Ash M. Contemporary Diag- nosis and Management of Type 2 Diabetes Second edition Pennsylvania, USA, Handbooks in health Care Co. Türk- çe: Karpuz H, Karpuz V, çeviri editörleri: Tip 2 Diyabet Güncel Tanı ve Tedavi İstanbul Avrupa Tıp Kiyapçılık 2004;264-285.
• Raptis AE, Viberti G. Pathogenesis of diabetic nephropathy. Exp Clin Endocrinol Diabetes 2001;109:424-437.
• Hillman N, Herranz L, Grande C, et al. What is the relative contribution of blood glucose levels at different time points of the day to HbA1c in Type 1 diabetes? Diabet Med 2004; 21:468-470.